.x.
Future and upcoming non-neoplastic applications of PET/CT imaging.
Hashefi M, Curiel R.
Division of Rheumatology, George Washington University, Washington,
District of Columbia, USA. mhashefi@mfa.gwu.edu
Abstract
The role of fluoro-2-deoxyglucose (FDG) positron emission tomography
(PET) in the diagnosis, staging, and monitoring of neoplastic
conditions is well established.
The clinical utility of PET/CT has now expanded to the diagnosis of
autoimmune, inflammatory, infectious, as well as non-neoplastic
conditions, such as the vasculitides, atherosclerosis, and
granulomatous conditions, including sarcoidosis and inflammatory bowel
disease, in addition to a variety of neurologic disorders.
The availability of new PET radiotracers is expected to expand PET/CT
applications to a variety of other clinical domains. New radioligands
for studying inflammation and neurodegenerative processes are under
development. Here, we discuss the evolving potential role of PET
imaging for the evaluation and monitoring of miscellaneous conditions,
including osteoarthritis, interstitial lung disease, vascular
thromboses, and osteoporosis.
=A9 2011 New York Academy of Sciences.
PMID: 21718331 [PubMed - indexed for MEDLINE]
---------------------------------------------
Send posts to CO-CURE@listserv.nodak.edu
Unsubscribe at http://www.co-cure.org/unsub.htm
---------------------------------------------
Co-Cure's purpose is to provide information from across the spectrum of
opinion concerning medical, research and political aspects of ME/CFS and/or
FMS. We take no position on the validity of any specific scientific or
political opinion expressed in Co-Cure posts, and we urge readers to
research the various opinions available before assuming any one
interpretation is definitive. The Co-Cure website <www.co-cure.org> has a
link to our complete archive of posts as well as articles of central
importance to the issues of our community.
---------------------------------------------
